

Supplemental Table 20. Changes in Oxidative Stress markers after 6 weeks of treatment

| Variable | Treatment | | | | | | Changes among treatments | | | | | |
|---------------------------------|---------------|-----------------------|--------------|-----------------------|---------------|-----------------------|--------------------------|--------------|------------------------|-------|------------------------|-------|
| | WFA (n=37) | | AI (n=38) | | RFA (n=32) | | AI vs WFA | | RFA vs WFA | | RFA vs AI | |
| | Post-int | Change | Post-int | Change | Post-int | Change | Mean (95%CI) | P | Mean (95%CI) | P | Mean (95%CI) | P |
| <i>Oxidative stress markers</i> | | | | | | | | | | | | |
| OxLDL, U/L | 72 ± 25 | 0.812 (-4.4;6.0) | 69 ± 23 | -0.551 (-5.6; 4.5) | 67 ± 33 | 3.26 (-2.4; 8.9) | -1.36 (-8.6;5.9) | 0.710 | 2.45 (-5.4;10) | 0.539 | 3.81 (-3.7;11) | 0.319 |
| OxLDL adjusted, U/cg of LDL | 0.51 ± 0.13 | 0.015 (-0.02;0.05) | 0.51 ± 0.14 | 0.021 (-0.01;0.05) | 0.47 ± 0.11 | 0.012 (-0.02;0.05) | 0.006 (-0.04;0.05) | 0.799 | -0.003 (-0.05;0.05) | 0.917 | -0.009 (-0.06;0.04) | 0.726 |
| <i>PON1 mass, mg/dL</i> | | | | | | | | | | | | |
| Total | 175 ± 40 | 5.83 (-3.3; 15) | 193 ± 50 | -3.09 (-12; 5.8) | 173 ± 33 | -2.95 (-13;6.9) | -8.92 (-18;8.6) | 0.172 | -7.97 (-22;3.9) | 0.259 | -8.79 (-22;4.9) | 0.207 |
| Men (n=47) | 174 ± 34 | 9.45 (-7.4; 26) | 210 ± 57 | 8.53 (-5.4; 22) | 169 ± 39 | 2.16 (-13;17) | -0.920 (-23;31) | 0.934 | -7.29 (-29;15) | 0.509 | -6.37 (-27;14) | 0.543 |
| Women | 175 ± 43 | 1.89 | 177 ± 37 | -14.8 | 176 ± 27 | -4.51 | -16.7 | 0.039 | -6.41 | 0.480 | 10.3 | 0.262 |

| | | | | | | | | | | | | |
|--------------------------------|-------------|---------------|-------------|-------------------|-------------|----------------------|--------------------|-------|----------------------|--------------|---------------------|--------------|
| (n=60) | | (-8.8; 12) | | (-27;-3.0) | | (-18; 9.2) | (-33;-0.83) | | (-24;12) | | (-7.9;28) | |
| PON raw, U/L | 2.43 ± 0.21 | -0.010 | 2.43 ± 0.23 | -0.018 | 2.38 ± 0.18 | 0.048 | -0.008 | 0.730 | 0.058 | 0.039 | 0.066 | 0.022 |
| (log) | | (-0.04; 0.02) | | (-0.05; 0.02) | | (0.006; 0.09) | (-0.05; 0.04) | | (0.003; 0.11) | | (0.01; 0.12) | |
| Arylest raw, U/L | 107 ± 24 | -1.62 | 111 ± 24 | 2.91 | 113 ± 27 | -2.02 | 4.53 | 0.197 | 0.400 | 0.916 | -4.93 | 0.175 |
| | | (-6.6; 3.3) | | (-1.8; 7.7) | | (-7.4; 3.3) | (-2.4 ; 11) | | (-7.9; 7.1) | | (-12; 2.2) | |
| PON specific, U/mg prot | | | | | | | | | | | | |
| Total | 1.79 ± 0.98 | -0.076 | 1.63 ± 0.81 | -0.007 | 1.48 ± 0.57 | 0.053 | 0.068 | 0.336 | 0.129 | 0.120 | 0.060 | 0.439 |
| | | (-0.18; 0.03) | | (-0.11; 0.09) | | (-0.06; 0.17) | (-0.08; 0.22) | | (-0.03; 0.29) | | (-0.09; 0.21) | |
| Men | 1.62 ± 0.83 | -0.146 | 1.43 ± 0.88 | -0.087 | 1.52 ± 0.77 | -0.008 | 0.058 | 0.624 | 0.138 | 0.263 | 0.080 | 0.452 |
| (n=47) | | (-0.33; 0.04) | | (-0.23; 0.06) | | (-0.16; 0.15) | (-0.18; 0.29) | | (-0.11; 0.38) | | (-0.13; 0.29) | |
| Women | 1.87 ± 1.07 | -0.029 | 1.83 ± 0.70 | 0.062 | 1.46 ± 0.87 | 106 | 0.092 | 0.372 | 0.135 | 0.261 | 0.043 | 0.716 |
| (n=60) | | (-0.17; 0.11) | | (-0.09; 0.21) | | (-0.07; 0.28) | (-0.11; 0.30) | | (-0.10; 0.37) | | (-0.19; 0.28) | |
| Arylest specific, U/mg prot | 0.64 ± 0.23 | -0.015 | 0.62 ± 0.21 | 0.016 | 0.68 ± 0.23 | 0.005 | 0.031 | 0.312 | 0.020 | 0.547 | -0.011 | 0.728 |
| | | (-0.06; 0.03) | | (-0.03; 0.06) | | (-0.04; 0.05) | (-0.03; 0.09) | | (-0.05; 0.09) | | (-0.07; 0.05) | |

Post-int, post-treatment values. Change, change from baseline. PON, paraoxonase; Arylest, arylesterase. Data expressed as mean ± standard deviation or mean (95% Confidence Interval, CI. ANCOVA Model adjusted by sex, age, difference of PUFA as percentage of energy intake, and baseline values. Significant differences depicted in **bold** and borderline ones in *italic bold*. When interaction with sex was significant, results were examined separately by sex